<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR55">
 <label>55.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Feld</surname>
    <given-names>JJ</given-names>
   </name>
   <name>
    <surname>Bernstein</surname>
    <given-names>DE</given-names>
   </name>
   <name>
    <surname>Younes</surname>
    <given-names>Z</given-names>
   </name>
   <name>
    <surname>Vlierberghe</surname>
    <given-names>HV</given-names>
   </name>
   <name>
    <surname>Larsen</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Tatsch</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Ferenci</surname>
    <given-names>P</given-names>
   </name>
  </person-group>
  <article-title>Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin</article-title>
  <source>Liver Int</source>
  <year>2018</year>
  <volume>38</volume>
  <issue>9</issue>
  <fpage>1571</fpage>
  <lpage>1575</lpage>
  <?supplied-pmid 29377566?>
  <pub-id pub-id-type="pmid">29377566</pub-id>
 </element-citation>
</ref>
